At present, glioma patients’ treatment options mainly depend on WHO classification (WHO I-IV) (3, 4), as well as molecular subtypes, like IDH mutations, 1p19q deletion status, and MGMT methylation (5–7). This evidence concerns the gene IDH1 and central nervous system cancer.